Catalogue number: 1001-15
The AroCell TK 210 ELISA is a microtiter plate sandwich-ELISA for the assay of serum Thymidine Kinase 1 (TK1).
The AroCell TK 210 ELISA is the first CE marked ELISA for TK1.
Serum TK1 is a valuable biomarker of cellular proliferation and it has been found to be elevated in subjects with many forms of cancer, including leukemia, lymphoma, prostate, breast, lung, sarcoma and colon cancer patients1.
However, previous methods have been based on enzyme activity measurements that may be subject to interference2 and may underestimate TK1, especially in serum from subjects with solid tumors. Furthermore, serum TK1 occurs as aggregates with a range of molecular weights and specific activities and this distribution differs between serum from healthy subjects and those with tumors3.
By utilising monoclonal antibodies specific for the TK1 epitope TK 210, the AroCell TK 210 brings improved sensitivity and specificity to the assay of this important biomarker, especially when studying serum TK1 derived from patients with solid tumors3,4.
The AroCell TK 210 ELISA procedure includes pre-treatment of the samples with a sample dilution buffer that releases TK1 from its aggregates and makes it more readily accessible for assay.
The AroCell TK 210 ELISA will provide new opportunities for studying cellular proliferation, tumor cell turnover and therapy response in subjects with solid tumors.
The AroCell TK 210 ELISA is for research use only in the USA.
|Assay Format||Microplate Sandwich ELISA|
|Sample||180 µL Human Serum|
|Incubation Time (Total)||4 hours 15 minutes|
|Calibration Curve||0 – 17 µg/L|
|Detection limit||0.19 µg/L|
|Precision||1.85 µg/L 5.1%|
11.53 µg/L 3%
|Dilution Recovery||Better than 5% deviation from linearity|
1. Alegre, M.M. et al. (2013). Thymidine Kinase 1: A Universal Marker for Cancer. Cancer and Clinical Oncology. 2(1): 2013.
2. He, Q. et al. (2006). Thymidine Kinase 1 in Serum Predicts Increased Risk of Distant or Loco regional Recurrence Following Surgery in Patients with Early Breast Cancer. Anticancer Research 26: 4753-4760.
3. Jagarlamudi. K.K. et al. (2015). Breast and Prostate Cancer Patients Differ Significantly in Their Serum Thymidine Kinase 1 (TK1) Specific Activities Compared with Those Found in Hematological Malignancies and Blood Donors: Implications of Using Serum TK1 as a Biomarker. BMC Cancer 15:66.
4. Kiran Kumar J et al, 2016. A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease. Tumor Biol, 37:11937-11945.